• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

89
16
14
8
8

COUNTRY

8
3
2
1
1

PRICE

68
102
206
272

PUBLISHED

21
28
52
272

PRODUCT TYPE

240
17
10
5

Women's Health

Women are increasingly attractive to pharmaceuticals company. From adolescence to old age they come into contact with the medical services far more than men, and this gives pharmaceutical companies the opportunity to target women as a distinct customer group characterized by brand loyalty. Business opportunities are also provided by the emerging countries, where women are increasingly empowered to access reproductive and other health services.

Browse Research and Markets’ Women’s Health category to identify investment, business development and partnership opportunities across a variety of issues such as contraception, pregnancy, female infertility, dysmenorrheal, menopausal disorders, ovarian disease, vaginal atrophy, and more. Monitor the latest drug trials, enhance your clinical knowledge and explore specific markets with our reports, books, and subscriptions.

Leading players featured in our publications include Wyeth, Schering, Johnson & Johnson, and more. Show Less
Read more

PRODUCT TITLE

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013', provides an overview of the indication’s...

September 2013
FROM

Female Sexual Dysfunction - Pipeline Review, H2 2013

Female Sexual Dysfunction - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Female Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

Uterine Fibroids - Pipeline Review, H2 2013

Uterine Fibroids - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Uterine Fibroids - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Women's Health - Pipeline Review, H2 2013

Women's Health - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Women's Health - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

September 2013
FROM

Dysmenorrhea - Pipeline Review, H2 2013

Dysmenorrhea - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Endometriosis - Pipeline Review, H2 2013

Endometriosis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Endometriosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Contraception - Pipeline Review, H2 2013

Contraception - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Contraception - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Colpotrophine (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Colpotrophine (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

Autoimmune Disorders - Pipeline Review, H2 2013

Autoimmune Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM

Estrace (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Estrace (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past...

July 2013
FROM

Lung Infections - Pipeline Review, H2 2013

Lung Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lung Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

July 2013
FROM

Pregnancy Global Clinical Trials Review, H2, 2013

Pregnancy Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Pregnancy Global Clinical Trials Review, H2, 2013" provides data on the Pregnancy clinical trial scenario. This...

July 2013
FROM

Vagifem (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Vagifem (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

Premarin (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Premarin (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - France Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Japan Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Germany Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over...

July 2013
FROM
Loading Indicator

Our Clients

Our clients' logos